Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: Ecole Polytechnique Fédérale de Lausanne, Laboratory of Microsystems LMIS4
Project no: GRS-041/16
Amount of funding: CHF 320'000
Duration: 05.2017 - 09.2019
Area of activity: Pilotprojekte, 1998 - 2018
Guillaume Petit-Pierre, Research Assistant
Ecole Polytechnique Fédérale de Lausanne
Laboratory of Microsystems
1015 Lausanne (Schweiz)
- guillaume.petit-pierre@epfl. ch
Today stroke is the second global-leading cause of death worldwide. In particular, hemorrhagic strokes - bleeding in the brain - are particularly dangerous with a mortality and severe disabilities rate close to 50%. It affects 660'000 persons annually and most often young people aged between 30 and 65. Unfortunately, these persons are still highly active and contributing to the society. One of the main cause for such a high mortality is attributed to a serious complication occurring in the brain; a spasm of the cerebral arteries. This abnormal blood vessels constriction leads to a lack of oxygen and nutriments in the cerebral tissues with dramatic consequences; entire brain regions can be destroyed. According to the physicians involved in the management of cerebral diseases, this complication is highly dangerous, difficult to detect and lacks any safe treatments.
In order to address this medical need, a drastically new therapy is investigated at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in collaboration with the Bern University Hospital (Inselspital). The therapy is based on state-of-the-art microtechnologies applied to medicine. VascuSAFE is a novel generation of catheter which is aimed to be introduced in the cerebral vascular system in order to perform a «reset» of the arteries leading to the release of the spasm.
Based on several years of research, this novel catheter and minimally invasive therapy could become a future standard of care for the efficient management of patients affected by hemorrhagic stroke. This technology is ultimately intended to save patients’ lives while fighting the disastrous consequences of hemorrhagic stroke.
What is special about the project?
The project proposed here is particularly innovative both in term of technologies employed and of medical therapy targeted. Indeed, the solution we intend to implement benefits from the latest microfabrication methods allowing to drastically reduce the size and precisely controlling the function of the device while guarantying components biocompatibility. Another key element of the project is the therapy itself which will be rapid, safe and induce no pain to the patient. The use of endovascular procedure ensures to remain minimally invasive; the brain arteries can be reached with a catheter from a single femoral artery access thus avoiding complex «open-brain» surgeries.
The project is currently in its startup phase. The medical need has been validated with multiple actors involved with the management of hemorrhagic stroke complications. VascuSAFE active catheter prototype have been developed, constructed and are currently being tested at EPFL laboratories. An in vivo study will be conducted in collaboration with the Bern Inselspital. This study aims to deliver the proof that VascuSAFE therapy will largely benefit to the positive outcome of hemorrhagic stroke patients.
No publication to date
No publication to date
Persons involved in the project
Last update to this project presentation 03.07.2019